三生制药（01530）今日盘中大涨14.23%，股价创下新高，引发市场广泛关注。截至盘中，该股报价已达到12.46港元左右，成交活跃。
消息面上，三生制药近期发布了2024年度业绩报告，显示公司业绩增长强劲。报告显示，集团期内实现收入91.08亿元人民币，同比增长16.5%；母公司拥有人应占纯利20.90亿元，同比增长34.9%。每股基本盈利达0.86元，公司拟派发末期股息每股25港仙。收入增长主要得益于特比澳、蔓迪及赛普汀等产品销售额的强势增长。
展望未来，三生制药的发展前景被市场看好。公司计划在2025年积极推进多个创新药物的商业化准备工作，包括柏瑞素、特艾升和丽美治等。更值得注意的是，公司预计从2025年开始，每年都将有重点新药进入商业化阶段。这一战略布局大大增强了投资者对公司未来增长潜力的信心，成为推动股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.